Shares of Illumina, Inc. (NASDAQ:ILMN) have received an average recommendation of “Buy” from the twenty-five ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fourteen have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $205.83.

ILMN has been the topic of several analyst reports. Barclays upped their target price on Illumina from $150.00 to $185.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 25th. Zacks Investment Research upgraded Illumina from a “hold” rating to a “buy” rating and set a $229.00 target price on the stock in a report on Friday, October 27th. Canaccord Genuity reiterated a “buy” rating and set a $230.00 target price (up previously from $215.00) on shares of Illumina in a report on Thursday, October 12th. Piper Jaffray Companies reiterated an “overweight” rating and set a $226.00 target price (up previously from $202.00) on shares of Illumina in a report on Monday, October 9th. Finally, Janney Montgomery Scott upgraded Illumina from a “sell” rating to a “neutral” rating in a report on Monday, October 23rd.

In other Illumina news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $211.11, for a total value of $4,222,200.00. Following the sale, the director now owns 539,176 shares in the company, valued at $113,825,445.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Oene Mark Van sold 9,729 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57. Following the completion of the sale, the senior vice president now owns 24,908 shares in the company, valued at approximately $5,263,807.64. The disclosure for this sale can be found here. Insiders sold 166,150 shares of company stock worth $34,767,331 in the last 90 days. Corporate insiders own 0.89% of the company’s stock.

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Illumina by 2.6% in the second quarter. Vanguard Group Inc. now owns 9,904,340 shares of the life sciences company’s stock valued at $1,718,601,000 after purchasing an additional 255,498 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Illumina by 3.1% in the third quarter. Ameriprise Financial Inc. now owns 2,512,167 shares of the life sciences company’s stock valued at $500,416,000 after purchasing an additional 76,452 shares during the last quarter. Capital World Investors grew its position in shares of Illumina by 23.8% in the second quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after purchasing an additional 410,000 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in shares of Illumina by 55.6% in the second quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after purchasing an additional 527,548 shares during the last quarter. Finally, Winslow Capital Management LLC acquired a new position in shares of Illumina in the second quarter valued at approximately $211,584,000. 91.75% of the stock is currently owned by institutional investors.

Illumina (NASDAQ:ILMN) traded down $3.54 on Friday, reaching $214.11. The company had a trading volume of 677,611 shares, compared to its average volume of 953,297. Illumina has a fifty-two week low of $121.47 and a fifty-two week high of $230.72. The company has a market capitalization of $31,776.90, a price-to-earnings ratio of 63.64, a PEG ratio of 3.59 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. During the same quarter in the prior year, the company posted $0.97 earnings per share. Illumina’s revenue was up 17.6% on a year-over-year basis. equities research analysts anticipate that Illumina will post 3.75 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Brokerages Set Illumina, Inc. (ILMN) Price Target at $205.83” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was copied illegally and reposted in violation of U.S. & international copyright laws. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/11/brokerages-set-illumina-inc-ilmn-price-target-at-205-83.html.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.